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Abstract
Trastuzumab improves survival outcomes for patients with HER2-positive (HER2þ) breast cancer, yet not all such
women receive this important therapy. Trastuzumab was approved by the US Food and Drug Administration in 1998
and the European Medicines Agency in 2000 as treatment for HER2þ metastatic breast cancer (MBC). Observational
studies between 2000 and 2015 in patients with HER2þ MBC suggest that nearly 12% in the United States, 27% to
54% in Europe, and 27.1% to 49.2% in China did not receive trastuzumab or any other HER2-targeted agent as ﬁrst-
and/or later-line for treatment of metastatic disease. In 2006, both agencies approved trastuzumab as adjuvant
therapy for patients with HER2þ early breast cancer (EBC). Observational studies on real-world treatment patterns for
HER2þ EBC between 2005 and 2015 suggest that 19.1% to 59.5% of patients across regions of North America,
Europe, Australia, New Zealand, and China did not receive (neo)adjuvant trastuzumab. Data suggest that some patient
subgroups, including older patients, those with HER2þ/hormone receptor-positive disease, and women with small
and/or node-negative HER2þ tumors, were less likely to receive anti-HER2 therapy. Barriers to accessing trastuzumab
are multifactorial and include issues related to drug funding and high treatment costs for patients that have been
reported worldwide. Herein, we review available literature on the use of, and barriers to, treatment with trastuzumab in
patients with HER2þ breast cancer. We also discuss how the availability of safe and effective biosimilars might in-
crease access to trastuzumab and allow greater use of anti-HER2 therapy, potentially improving patient outcomes.
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Between 15% and 20% of patients with breast cancer have
HER2-positive (HER2þ) disease.1,2 Trastuzumab, a recombinant
humanized monoclonal antibody against HER2, was approved by
the US Food and Drug Administration (FDA) in 1998 and the
European Medicines Agency (EMA) in 2000 for use in patients
with HER2þ metastatic breast cancer (MBC).3,4 Subsequently,
trastuzumab was approved by the EMA and FDA as adjuvant
therapy (2006) and by the EMA as neoadjuvant therapy (2011) for
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(WHO) Model List of Essential Medicines.5
Targeted therapy with trastuzumab and/or other currently
available HER2-directed agents, including pertuzumab, lapatinib,
and ado-trastuzumab emtansine (T-DM1), is standard treatment for
patients with HER2þ breast cancer, and clinical guidelines recom-
mend trastuzumab-based chemotherapy (along with pertuzumab) as
(neo)adjuvant treatment for HER2þ EBC and in the metastatic
setting.6-10 Although trastuzumab was initially evaluated and used
in the ﬁrst-line metastatic setting,11 in some countries it became
common practice to continue trastuzumab at progression, which
improves patient outcomes.12 However, multiple lines of HER2
blockade, as well as combinatorial treatment strategies, have sig-
niﬁcant cost implications for patients and health care systems.
Patents for several biologic drugs, including trastuzumab,
have recently expired or will soon expire,13 which has stimulated
the development of biosimilars. Biosimilars are biologic products that
are highly similar to a licensed biologic (ie, the reference or originator
product), “notwithstanding minor differences in clinically inactive
components,” and have no clinically meaningful differences in safety,
purity, or potency compared with the reference product.14-16Clinical Breast Cancer April 2018 - 95
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Need for Trastuzumab Biosimilar for HER2-Positive Breast CancerBiosimilars might increase access to biologics. For example, use of
granulocyte colony-stimulating factor in the United Kingdom
increased more than 30% in the ﬁrst 2 years after the introduction of
biosimilar ﬁlgrastim.17 Cost savings from the use of a biosimilar also
might allow for expanded access to other novel therapies, indirectly
leading to better overall health outcomes. For example, a study
calculated that the potential cost savings generated by switching
100,000 patients in Germany, France, Italy, Spain, and the United
Kingdom from originator epoetin to biosimilar epoetin could support
an additional 9770 to 12,913 rituximab, 3912 to 5171 bevacizumab,
or 3713 to 4908 trastuzumab treatments.18
Access to trastuzumab might be limited for various reasons such as
lack of drug funding or because of treatment costs,19-21 and real-world
data show that not all patients with HER2þ breast cancer receive
trastuzumab.22-44 This review discusses the use of, and barriers to,
treatment with trastuzumab in patients with HER2þ breast cancer,
and how the introduction of trastuzumab biosimilars might address
the needs of patients and the wider health care system.
Patterns of Trastuzumab Use
Worldwide
Patterns of Use in EBC
In a 2011 international physician survey, 92% of respondents
(N ¼ 151) indicated that they routinely recommend 1 year of
adjuvant trastuzumab; however, 47% reported having at least 1 case
within the previous year in which trastuzumab was recommended
but treatment could not be started.19 Failure to start recommended
trastuzumab was more commonly reported by physicians from low-
and middle-income countries (75%) than high-income countries
(40%; P ¼ .005) and most often cited by respondents from Africa
(100%), Asia (89%), and Latin America (80%).19 Observational
studies on real-world treatment patterns in patients diagnosed with
and/or treated for HER2þ EBC between 2005 and 2015 suggest
that 19.1% to 59.5% in the United States, Canada, Australia, New
Zealand, United Kingdom, The Netherlands, Germany, and
China did not receive neoadjuvant or adjuvant trastuzumab
(Table 1).23-25,30-32,34-37,39-41,44,45 Use of trastuzumab was some-
what less in patients with small (1 cm) and/or node-negative
HER2þ tumors,28,30,40,41,44 in whom the beneﬁts of adjuvant
trastuzumab therapy are somewhat controversial.7,9,10
Several studies conducted between 2006 and 2013 also suggest that
older patients with HER2þ EBC and patients with HER2þ/hormone
receptor (HR)-positive disease were less likely to receive trastuzumab-
based therapy (Table 1).24,30,34,35,39,41 Of these patients, approxi-
mately 50% of those aged 65 years or older in the United States,
47.1% (32 patients) older than 69 years in Germany, and 67% (176
patients) older than 70 years in Australia and New Zealand did not
receive trastuzumab-based therapy (Table 1).34,35,39,41 Lesser use of
trastuzumab in older patients might reﬂect, in part, increased comor-
bidities. However, among women of this older age group in the United
States, those who resided in impoverished neighborhoods or who were
black were less likely to receive trastuzumab-based therapy
(Table 1).35,39 Similar to the overall population, older women with
more favorable disease characteristics, including those with
HRþ tumors, small tumors, or no lymph node involvement, were also
less likely to receive adjuvant trastuzumab.35,39Clinical Breast Cancer April 2018Patterns of Use in MBC
A prospective, US-based observational cohort study (registHER) that
enrolled patients withHER2þMBC between 2003 and 2006 reported
that approximately 12% (121 patients) did not receive ﬁrst-line tras-
tuzumab-based systemic therapy (Table 2).22,26,27,29,33,38,42,43,45 The
percentage of registHER patients with HER2þ MBC who did not
receive trastuzumab-based therapy as ﬁrst- or later-line treatment was
somewhat greater amongpatientswithHRþ tumors (17%,90patients),
older patients (75 years or older; 23%, 15 patients), and those with
central nervous system metastases (approximately 32%, 119 patients;
Table 2).22,29,38 Similarly, preliminary results from another US-based,
observational cohort study in patients diagnosed with HER2þ MBC
between 2009 and 2011 showed that approximately 45% (34 patients)
of those with brain metastases did not receive ﬁrst-line treatment with
trastuzumab.33 Thismight reﬂect concerns regarding the penetration of
trastuzumab, although recent datawithT-DM1aswell as etirinotecan (a
pegylated irinotecan) show that macromolecules can be effective treat-
ment against brain metastases.46,47
An observational study of patients in China with HER2þ invasive
breast cancer who received hospitalized therapy between 2010 and
2015 reported that 27.1% of those with metastatic disease did not
receive trastuzumab at any time after diagnosis and 49.2% did not
receive trastuzumab in the ﬁrst-line setting.45 An analysis of drug
utilization among patients with HER2þ breast cancer in Sweden
estimated that approximately 27% of those with metastatic disease did
not receive trastuzumab in 2004.42 However, this estimate was only 4
years after trastuzumab was approved in Europe, during which time
trastuzumab use rose from11% (2000) to 73% (2004).42 A European-
based, observational cross-sectional study of patients diagnosed with or
treated for MBC in 2008 showed that approximately 54% (712 pa-
tients) of those with HER2þ tumors in France, Germany, Spain, Italy,
and the United Kingdom did not receive HER2-targeted or
trastuzumab-based systemic therapy as part of their most recent
regimen (Table 2).27 Consistent with US data, treatment differences
according to HR status were also evident in Europe. For example,
approximately 61% (491 patients) with HER2þ/HRþ and 44% (221
patients) with HER2þ/HR tumors did not receive HER2-targeted
therapy as part of their most recent regimen (Table 2).27 Another
study that investigated treatment patterns according to HR andHER2
status in those same 5 European countries and during a similar time
frame (2008 and 2010) also showed less frequent use of anti-HER2
therapy among patients with HER2þ/HRþ than those with
HER2þ/HR tumors.26 Overall, across countries, approximately
36% to 74% of patients withHER2þ/HRþ and 25% to 49% of those
withHER2þ/HR tumors did not receive anti-HER2 therapy as ﬁrst-
line treatment in the metastatic setting.26
Reasons for Patients Not Receiving Anti-HER2 Therapy
Few studies in patients with EBC, and none in patients with
MBC, reported reasons for patients not receiving anti-HER2 ther-
apy.23,25,30,32,36,37,40,44 Furthermore, it is not clear how often
HER2 blockade is continued in multiple lines of systemic therapy
for metastatic disease. In the adjuvant setting (Table 1), trastuzu-
mab was withheld from patients because of advanced age (11%-
23%), increased risk of cardiac toxicity (15%-46.4%), or other
comorbidities (approximately 12%).23,25,36,37,40 In other cases,
Table 1 Observational Studies of Real-World Treatment Patterns in Patients With HER2D EBC: Use of Neoadjuvant and Adjuvant Trastuzumab
Reference (Country) Patient Population (Setting) Study Observation Period
Patients With
HER2D BC, n
Patients
Received
Trastuzumab, %
Patients Did
Not Receive
Trastuzumab, %
Reasons for Withholding
Trastuzumab
Overall Population
Kurian et al30 (US) Stage I-III BC (adjuvant) Dx 2004-2007; Tx within 1 year of Dx 287a 68.3 31.7 NR
Stenehjem et al37 (US) Women with stage I-IIIA BC (adjuvant) Dx January 2005 to December 2012;
follow-up until April 2013 or death,
whichever occurred ﬁrst
245 75.9b 24.1 Low risk of recurrence: 30.5%
Unknown: 18.6%
Age or comorbidity: 16.9%
Loss to follow-up: 15.3%
Patient declined: 11.9%
Patient relocated: 6.8%
DaCosta Byﬁeld et al24 (US) Commercially insured (aged 18 years) with
HER2þ stage I-III BC (neoadjuvant or adjuvant)
Dx January 2008 to August 2013 915 72c 28 NR
HRþ: 662 69 31
HR: 253 80 20
P < .01d
Noonan et al32 (CA) HER2þ stage I-III BC (adjuvant) Dx January 2005 to January 2010;
median follow-up 25 months
148 76 24 Small tumor size (T1a),
comorbidities, and patient
preference
Zurawska et al44 (CA) Women (18 years) with stage I-III
invasive BC (adjuvant)
Dx January 2005 to December 2006;
median follow-up 62 months (range,
17 days to 85 months)
94 80.9 19.1 Subcentimeter tumors (presumably
reason for withholding trastuzumab):
55.5%
No reason provided: 27.8%
Declined systemic Tx: 16.7%
Coulson et al23 (UK) Nonmetastatic BC (adjuvant) Dx September 2007 to August 2008 199 67 33 Age >75 years: 23%
Patient refusal: 20%
Clinician recommend/unfavorable
risk-beneﬁt ratio: 19%
High cardiac risk: 15%
Other comorbidities: 12%
General frailty/poor PS: 6%
Unﬁt for surgery/primary endocrine
therapy: 6%
Webster et al40 (UK) HER2þ stage I-III BC (adjuvant) Dx January 2005 to December 2008 338 70.7 29.3 Not treated with CTX (n ¼ 71;
71.7%): reasons for withholding
trastuzumab not reported
Treated with CTX (n ¼ 28; 28.3%):
Cardiac comorbidity: 46.4%
Patient refusal: 25.0%
Lack of funding in period before
NICE approval: 10.7%
Clinician recommendation/perceived
low recurrence risk: 10.7%
Disease recurrence before
trastuzumab: 7.4%
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Table 1 Continued
Reference (Country) Patient Population (Setting) Study Observation Period
Patients With
HER2D BC, n
Patie s
Recei d
Trastuzum b, %
Patients Did
Not Receive
Trastuzumab, %
Reasons for Withholding
Trastuzumab
de Munck et al25 (NL) Women with invasive nonmetastatic BC
(adjuvant)
Dx September 2005 to January 2007 1928 55 45 NR
Received adjuvant
CTX: 1114
94 6 No reason given: 36%
Cardiac toxicity: 29%
Patient refusal: 21%
Age: 11%
Other: 3%
Seferina et al36 (NL) Stage I-III invasive BC (adjuvant) Dx January 2005 to December 2007;
follow-up to October 2011
476 48.3 51.7 NR
Eligible for adjuvant
trastuzumab per
guidelines: 251
78.1 21.9 Cardiac comorbidities: 33%
Borderline indication for
trastuzumab: 20%
Patient preference: 15%
Not yet prescribed by hospital (Dx
before March 1, 2005): 13%
Other comorbidities: 11%
Early stop of CTX because of side
effects: 7%
Other disease characteristics: 2%
Liebrich et al31 (GE) BC (neoadjuvant, adjuvant, palliative) Dx in 2007; follow-up data up to May 2009 Invasive BC: 785 61 39 NR
Eligible for adjuvant
trastuzumab per
guidelines: 433
77 23 NR
Peters et al34 (GE) Women with nonmetastatic invasive BC
(adjuvant)
Dx and biopsy in 2006-2011; follow-up
data up to 2013
331 77 23 NR
Whitﬁeld et al41 (AU and NZ) Invasive BC (adjuvant) Tx January 2006 to December 2008 Tx in 2008: 908 74 26 NR
Li et al45 (CN) HER2þ invasive BC (neoadjuvant or adjuvant) Tx January 1 2010 to October 30 2015 1017 40.5 59.5 NR
Older Patients
Reeder-Hayes et al35 (US) Women (65 years) with HER2þ stage I-III
invasive BC (neoadjuvant or adjuvant)
Dx in 2010 and 2011; Tx within
1 year of Dx
1362 49 51 NR
White: 1162 50 50
Black: 104 40 60
Other minority: 96 52 48
Vaz-Luis et al39 (US) Women (66 years) with HER2þ stage IB-III
invasive BC without history of CHF (adjuvant)
Dx in 2010-2011; Tx within 9 months of Dx 770 55.6 44.4 NR
66-70 years: 252 71.0 29.0
71-75 years: 170 68.8 31.2
76-80 years: 152 47.4 52.6
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Table 1 Continued
Reference (Country) Patient Population (Setting) Study Observation Period
Patients With
HER2D BC, n
Patients
Received
Trastuzumab, %
Patients Did
Not Receive
Trastuzumab, %
Reasons for Withholding
Trastuzumab
80 years: 196 30.6 69.4
P < .001d
Non-Hispanic white: 620 56.5 43.6
Non-Hispanic black: 45 35.6 64.4
Hispanic/other/unknown:
105
59.1 40.9
P ¼ .02d
HRþ: 557 51.9 48.1
HR: 213 65.3 34.7
P < .001d
Peters et al34 (GE) Women with nonmetastatic invasive BC
(adjuvant)
Dx and biopsy 2006-2011; follow-up
data up to 2013
<50 years: 75 93.3 6.7 NR
50-69 years: 188 79.3 20.7
>69 years: 68 52.9 47.1
P < .001d
Whitﬁeld et al41 (AU and NZ) Invasive BC (adjuvant) Tx January 2006 to December 2008 70 years: 1741 75 25 NR
>70 years: 264 33 67
P < .001d
Patients With Small and/or
Node-Negative Tumors
Zurawska et al44 (CA) Women (18 years) with stage I-III
invasive BC (adjuvant)
Dx January 2005 to December 2006;
median follow-up 62 months (range,
17 days to 85 months)
Node-negative tumors
<1 cm: 13
23.1 76.9 NR
Webster et al40 (UK) HER2þ stage I-III BC (adjuvant) Dx January 2005 to December 2008 Node-negative tumors
1 cm: 25
28 72 NR
Whitﬁeld et al41 (AU and NZ) Invasive BC (adjuvant) Tx January 2006 to December 2008 Tx in 2008,
node-positive: 450
84 16 NR
Tx in 2008,
node-negative tumors
>1 cm: 326
71 29 NR
Tx in 2008,
node-negative tumors
1 cm: 132
43 57 NR
Abbreviations: AU ¼ Australia; BC ¼ breast cancer; CA ¼ Canada; CHF ¼ congestive heart failure; CN ¼ China; CTX ¼ chemotherapy; Dx ¼ diagnosis; EBC ¼ early breast cancer; GE ¼ Germany; HR ¼ hormone receptor; NICE ¼ National Institute for Health and Clinical
Excellence; NL ¼ The Netherlands; NZ ¼ New Zealand; PS ¼ performance status; Tx ¼ treatment; UK ¼ United Kingdom; US ¼ United States.
aAnalysis of trastuzumab use was limited to 2006-2007 because adjuvant trastuzumab was not approved by the US Food and Drug Administration until 2006.
bIncludes 1 patient who received adjuvant lapatinib.
cIncludes 4 patients who received adjuvant lapatinib in addition to trastuzumab.
dStatistically signiﬁcant difference.
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Table 2 Observational Studies of Real-World Treatment Patterns in Patients With HER2D MBC: Use of Anti-HER2 Therapya
Reference (Country)
Patient Population
(Setting) Study Observation Period
Patients With
HER2D MBC, n
Patients Did
Receive
HER2-Targeted
Therapy
Patients Did
Not Receive
HER2-Targeted
Therapy
Yardley et al43 (US) HER2þ MBC (ﬁrst-line) Enrolled December 2003 to February 2006;
followed until death, disenrollment, or study
end (June 2009)
De novo: 327 88.1% 11.9%
Recurrent: 674 87.8% 12.1%
Kaufman et al29 (US) HER2þ MBC (ﬁrst-line) Enrolled December 2003 to February 2006;
followed until death, disenrollment, or study
end (June 2009)
<65 years: 792 85% 15%
65-74 years: 144 81% 19%
75 years: 65 77% 23%
Tripathy et al38 (US) HER2þ MBC (ﬁrst-line) Enrolled December 2003 to February 2006;
followed until death, disenrollment, or study
end (June 2009)
HRþ: 530 83% 17%
Patt et al33,b (US) HER2þ MBC (ﬁrst-line) Dx January 2009 to December 2011;
follow-up through November 2014
Brain
metastases and
systemic Tx: 75
54.7% 45.3%
Brufsky et al22 (US) HER2þ MBC
(ﬁrst- or later line)
Enrolled December 2003 to February 2006;
followed until death, disenrollment, or study
end (June 2009)
CNS
metastases: 377
68.4% 31.6%
Wilking et al42 (SE) HER2þ MBC
(ﬁrst- or later line)
Last quarter 2000 through end of 2004c 2000: 190 11% 89%
2001: NR 19% 81%
2002: NR 33% 67%
2003: NR 47% 53%
2004: NR 73% 27%
Gao et al27
(FR, GE, IT, SP, UK)
Women (21 years) with
MBC (ﬁrst- or later line)
Dx or Tx at any time during 2008 1311 46% 54%
HRþ: 809 39% 61%
HR: 502 56% 44%
DeKoven et al26 Patients (21 years)
with MBC (ﬁrst-line)
First Dx or relapse of MBC in July 2008
and June 2010
FR HRþ: 4887 63.8% 36.1%
HR: 3356 74.9% 25.1%
GE HRþ: 9491 40.5% 59.5%
HR: 5417 57.9% 42.1%
IT HRþ: 5294 37.4% 62.6%
HR: 3464 65.5% 34.5%
SP HRþ: 2106 35.5% 64.5%
HR: 1162 67.8% 32.2%
UK HRþ: 5382 26.5% 73.5%
HR: 3471 51.3% 48.7%
Li et al45 (CN) HER2þ invasive BC
ﬁrst-line
Tx January 1, 2010 to October 30, 2015 720 50.8% 49.2%
Overall 72.9% 27.1%
Abbreviations: BC ¼ breast cancer; CN ¼ China; CNS ¼ central nervous system; Dx ¼ diagnosis; FR ¼ France; GE ¼ Germany; HR ¼ hormone receptor; IT ¼ Italy; MBC ¼ metastatic breast
cancer; NR ¼ not reported; SE ¼ Sweden; SP ¼ Spain; Tx ¼ treatment; UK ¼ United Kingdom; US ¼ United States.
aHER2-targeted therapy consisted of trastuzumab in 7 studies,29,33,38,42,43,45 trastuzumab and/or lapatinib in 3 studies.22,26,27
bPreliminary results of a study presented at the 2016 American Society of Clinical Oncology Quality Care Symposium.33
cPercentages of patients who received trastuzumab was calculated using drug sales data received from the Retail Drug Supplier in SE, treatment recommendations by the Swedish Breast Cancer
Group, cancer and death statistics received from the National Board of Health and Welfare, general statistics (eg, population) obtained from Statistics Sweden, an estimated frequency of HER2
positivity of 25%, a treatment duration of 38 weeks, and an estimated use of 1 unit of trastuzumab per patient per week.
Need for Trastuzumab Biosimilar for HER2-Positive Breast Cancer
100 -patients declined systemic therapy or speciﬁcally refused trastuzu-
mab (11.9%-25%) or their oncologist advised against its use
because of a perceived low risk of recurrence or unfavorable
riskebeneﬁt ratio (10.7%-30.5%).23,25,32,36,37,40,44Clinical Breast Cancer April 2018Less frequently (2%-15.3%), trastuzumab was withheld
because of other patient-related factors (eg, loss to follow-up,
general frailty/poor performance status) or disease characteristics
(Table 1).23,25,36,37,40 In 1 United Kingdom-based study conducted
Kimberly Blackwell et albetween 2005 and 2008, 10.7% (3 patients) did not receive adju-
vant trastuzumab because they were treated before National Insti-
tute of Clinical Excellence approval of trastuzumab in 2006 made
funding for trastuzumab in this setting widely available.40 Finally,
18.6% (11 patients) in 1 US-based study, 27.8% (5 patients) in 1
Canadian-based study, and 36% (24 patients) in 1 European-based
study (The Netherlands) did not receive trastuzumab for unknown
or undocumented reasons.25,37,44
Summary
Observational studies suggest that, in the past, up to approxi-
mately 60% of patients with HER2þ breast cancer might not have
received anti-HER2 therapy at some point during their course of
treatment. Interpretation of these ﬁndings might be limited by the
accuracy of data reporting, and the analysis does not consider use of
anti-HER2 therapy in countries where trastuzumab is approved but
data for treatment patterns are not available. Additionally, estimates
of trastuzumab use at the time of data collection or reporting might
not be reﬂective of current treatment patterns or guidelines. It
should also be noted that several studies in patients with EBC re-
ported ﬁndings on the basis of data from patients who were diag-
nosed and/or treated between 2005 and 2008
(Table 1),23,25,30,31,36,40,41,44 which might not have captured or
been sufﬁcient to fully characterize trastuzumab use after expanded
approvals for adjuvant or neoadjuvant therapy.
Furthermore, the decision not to treat patients with trastuzumab
might have been appropriate in some situations, such as in patients at
increased risk of cardiac toxicity or other comorbidities.3,4 Indeed,
evidence suggests that up to nearly one-half of patients with HER2þ
EBC who did not receive adjuvant trastuzumab might not have been
eligible because of cardiac or other comorbidities.23,25,36,40 In addi-
tion, the prevalence of cardiovascular disease might be associated with
demographic factors (eg, age or race),48 which could explain, at least
in part, why certain patient subgroups appeared less likely to receive
HER2-targeted therapy. Nevertheless, real-world data show that not
all patients with HER2þ breast cancer receive HER2-targeted agents,
suggesting there might be opportunities for increasing access to
optimal anti-HER2 therapy.
Barriers to Accessing Trastuzumab
Physicians might decide not to prescribe anti-HER2 therapy in
situations where such treatment has regulatory approval but is not
funded or reimbursed. A survey of oncologists in the United States
and emerging markets (Brazil, Mexico, Turkey, and Russia) showed
that most physicians reported “always” or “frequently” prescribing
trastuzumab for patients with HER2þ breast cancer (neoadjuvant,
73%; adjuvant, 92%; metastatic, 92%). However, 31% (between
10% in the United States and 76% in Russia) of physicians in these
countries reported there had been at least 1 instance in which they
had to cancel or delay treatment because of reimbursement issues,
although it was not stated how often this precluded trastuzumab
use.21 Furthermore, among the small percentage of respondents
who reported “not so often,” “rarely,” or “never” prescribing tras-
tuzumab, between 37% and 49% considered lack of drug funding a
barrier to use in the neoadjuvant, adjuvant, and metastatic set-
tings.21 Reimbursement of anti-HER2 therapy also varies across
Europe, which might create disparities in accessing trastuzumab.20For example, trastuzumab is on formulary and available at low or
no out-of-pocket cost to patients with HER2þ breast cancer
throughout Western Europe; however, in several Eastern European
countries it is not reimbursed or as highly subsidized as in Western
Europe, leaving patients responsible for up to the full cost of
treatment.20
Reimbursement decisions are complex and might be inﬂuenced
by several factors.49 In many countries, cost-effectiveness informa-
tion is considered when making decisions about drug funding and
reimbursement. Economic evaluations of trastuzumab-based adju-
vant systemic therapy performed in high-income countries show
that trastuzumab is a highly cost-effective intervention for most
patients.50-52 However, trastuzumab-based adjuvant systemic ther-
apy is not considered cost-effective in several Latin American
countries53 and, like many therapeutic options, uncertainties remain
regarding its cost-effectiveness in the metastatic setting.54 This
might be of particular relevance to patients who receive multiple
lines of HER2 blockade for treatment of metastatic disease, because
the most clinically effective sequence might not be considered cost-
effective and, therefore, might not be reimbursed.55 Controversies
surrounding the cost-effectiveness of trastuzumab might contribute
to its limited accessibility in some patients and regions.
Another consideration for reimbursement is off-label regula-
tions.49 Public and/or private payers might not reimburse off-label
indications or might provide coverage of off-label indications only
when there is sufﬁcient evidence to support that use.49 This might
be relevant to certain subpopulations of patients with HER2þ breast
cancer. For example, guidelines recommend trastuzumab-based
adjuvant chemotherapy as an option for patients with small node-
negative HER2þ tumors, because this patient population remains
at higher risk of recurrence than those with node-negative HER2
tumors of the same size.7,9,10 However, direct evidence for efﬁcacy
of trastuzumab in small, node-negative HER2þ breast cancer is
lacking, reﬂecting the design of registration studies, and trastuzu-
mab is not approved for use in this setting.3,4,7,9,10
As a result of reimbursement strategies, some patients might face
greater economic burden, which might create a barrier to accessing
treatment.19-21 Among surveyed oncologists in the United States and
emerging markets who reported that they “not so often,” “rarely,” or
“never” use trastuzumab, 34% (of 137 respondents) and 42% (of 41
respondents) cited “high out-of-pocket treatment cost for patient” as
a barrier to use in the neoadjuvant and adjuvant settings, respec-
tively.21 In an international survey of physicians (N ¼ 151) con-
ducted in 2011, 27% of respondents who reported at least 1 instance
within the previous year in which adjuvant trastuzumab was rec-
ommended to a patient who ultimately did not receive it cited cost as
the reason for withholding treatment.19 Furthermore, cost was more
often cited by physicians in low- and middle-income countries (73%)
than in high-income countries (7%; P < .0001) as a reason for
withholding adjuvant trastuzumab.19
Biosimilars: A Pathway to
Increasing Trastuzumab Access in
HER2þ Breast Cancer Worldwide
Overview of Biosimilar Development
Traditional pharmaceutical agents are small, low molecular-
weight drugs with structures that are readily deﬁned and that canClinical Breast Cancer April 2018 - 101
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102 -be exactly replicated using chemical synthesis to create generic
copies.56 Biologics such as trastuzumab are high molecular-weight
proteins, often containing post-translational modiﬁcations, with
complex 3-dimensional structures that are difﬁcult to fully charac-
terize.56 Unlike small-molecule drugs, biologics are produced in
living systems through a series of biological reactions that are
inherently variable and sensitive to manufacturing and environ-
mental conditions.56 Because this has been long recognized, biologic
manufacturing is characterized by heterogeneity of the same biologic
product produced by different manufacturers and within/between
batches from the same manufacturer.
Manufacturers of an originator biologic have extensive knowledge
about the manufacturing process of their product.57 This infor-
mation is considered proprietary and conﬁdential; therefore, it is not
accessible to biosimilar manufacturers. For this reason, and because
of their complexity and heterogeneity, biologics cannot be exactly
replicated, so the concept of a generic equivalent and regulatory
approval requirements for small-molecule generics cannot be
applied to biologics.14,16 Therefore, regulatory agencies such as the
EMA and FDA, as well as the WHO, have issued guidelines for the
approval of biosimilars.14-16 All agencies require a rigorous stepwise
approach to comparing biosimilar and reference products that be-
gins with extensive structural and functional characterization
(Figure 1).14-16,58 Depending on the outcome of analytical (struc-
tural) and in vitro functional assessments, nonclinical in vivo testing
might be conducted to further evaluate drug safety,14-16 if deemed
necessary. Animal toxicity studies should show high similarity be-
tween the proposed biosimilar and reference products in terms of
their pharmacokinetics (PK) and pharmacodynamics (PD).15,16
These studies might also include immunogenicity assessments to
support the interpretation of nonclinical results.15,16,59 Nonclinical
assessments are followed by a limited number of comparative clin-
ical trials that are designed to show a high degree of pharmacologic
(PK/PD) and clinical (safety, efﬁcacy, and immunogenicity) simi-
larity to the reference product.14-16,59
In the United States, biosimilars are approved following a
pathway established by the Biologics Price Competition and
Innovation Act of 2009, which places greater emphasis on ﬁndings
from analytical and functional assessments than a full reference or
originator biologics application.15,60 When analytical and functional
similarity are established, biosimilar approval might rely, in part, on
the safety and efﬁcacy data that supported the approval of its
reference product, thereby reducing the extent of clinical testing
compared with that required for originator biologics.16,60 The need
for clinical testing to demonstrate similarity in drug safety and
efﬁcacy between the proposed biosimilar and reference product also
distinguishes the biosimilar pathway from that of small-molecule
generics.
Factors to Consider When Evaluating Trastuzumab
Biosimilars
The key to developing high-quality biosimilars rests on a
demonstration of physicochemical and functional similarity.14-16
The large size and complex structure of trastuzumab, as well as
differences in manufacturing processes, create the potential for
heterogeneous biologic products. Therefore, comparative physi-
cochemical analyses should be selected to detect differences inClinical Breast Cancer April 2018primary (ie, amino acid sequence), secondary, and higher-order
structures, post-translational modiﬁcations, product isoforms,
and product-related impurities (eg, protein aggregates;
Figure 2).14-16,61,62 To evaluate differences in biologic activity,
in vitro studies that measure target binding, tumor cell growth
inhibition, and antibody-dependent, cell-mediated cytotoxicity
should be selected.16,63
On the basis of the totality of the evidence from the preceding
steps, a comparative clinical pharmacology (PK/PD) study and a
comparative clinical efﬁcacy trial (or trials), including clinical
immunogenicity and safety assessments, are conducted to investi-
gate whether there are clinically meaningful differences between a
proposed biosimilar and reference product.14-16,59 This is in
contrast to new drug approvals, which require that large phase III
clinical trials are conducted in each indication for which licensure is
sought. In some cases, efﬁcacy end points that are selected for
biosimilar clinical trials will differ from those used in pivotal trials
that led to approval of the originator. Furthermore, whereas phase
III trials to support new drug approvals are designed to establish
“signiﬁcant” beneﬁt over a comparative agent, which is usually the
current standard treatment, biosimilarity studies are designed to
show that differences between treatment groups are not clinically
meaningful (ie, are small enough that the biosimilar is considered
neither superior nor inferior to the reference product and vice
versa).16,64 To this end, the most suitable design for biosimilarity
studies is a statistically driven equivalence trial in which equivalence
is shown when a given parameter (eg, the conﬁdence interval [CI])
falls within the lower and upper limits of a predetermined equiva-
lence margin.64
Regulatory guidelines for biosimilar development recommend
using patient populations, treatment settings, and clinical end
points that are adequately sensitive to detect all clinically meaningful
differences in efﬁcacy, safety, and immunogenicity between a bio-
similar and reference product.15,16,59,63 Furthermore, clinical end
points that measure activity (eg, tumor response), or PD measures
that correlate with clinical outcome, should be used in a homoge-
nous study population.16,63 The clinical setting (eg, neoadjuvant or
metastatic) and end points (eg, pathologic complete response [pCR]
and progression-free survival or objective response rate [ORR] in the
neoadjuvant and metastatic settings, respectively) used to establish
biosimilarity in HER2þ breast cancer might vary between different
trastuzumab biosimilar clinical development programs. However,
regulatory agencies will require adequate scientiﬁc justiﬁcation for
choice of these and other study design elements.15,16,59 It is unclear
to what extent study design might affect the choice of biosimilars in
clinical practice.
Regulatory agencies might also approve a biosimilar for use in
other indications for which it has not been studied in a comparative
clinical trial with the reference product but for which the reference
product is approved; this is known as “extrapolation.”14,16,65 For
example, extrapolation of data from comparative clinical studies that
establish biosimilarity in HER2þ EBC (eg, neoadjuvant setting) or
in patients with metastatic disease could support the approval of
trastuzumab biosimilars for use in other indications of trastuzumab.
However, extrapolation of data must be scientiﬁcally justiﬁed on the
basis of the totality of the data from all stages of biosimilar devel-
opment and other evidence that shows the reference product has
Figure 1 The Development of Originator Biologics Versus Biosimilars
Clinical
studies
Nonclinical
Analytical
Clinical
pharmacology/
PK/PD
Originator biologic
Requires extensive clinical testing to
establish drug safety and efficacy
Biosimilar biologic
Robust analytical characterization provides a strong rationale
for abbreviated nonclinical in vivo and clinical testing
Clinical
studies
Nonclinical
Analytical
Clinical 
pharmacology/
PK/PD
Abbreviations: PD ¼ pharmacodynamics; PK ¼ pharmacokinetics.
Adapted from Kozlowski S. Biosimilar biological products: overview of approval pathway under the biologics price competition and innovation act of 2009. Available at: https://c.ymcdn.com/sites/casss.
site-ym.com/resource/resmgr/WCBP_Speaker_Slides/2013_WCBP_Kozlowski_Steven.pdf.
Kimberly Blackwell et alsimilar therapeutic effects in the studied and extrapolated in-
dications. This concept of extrapolation is consistent with the
objective of biosimilar development, because it reduces or eliminates
the need for duplicative clinical studies. However, it is in contrast to
the development of originator drugs, for which speciﬁc clinical trial
data are required for each indication for which licensure of the
product is sought. It is unclear how receptive clinicians will be to the
concept of extrapolation.
Although the EMA and FDA guidelines for regulatory approval
of biosimilars continue to evolve, products that have been approved
using this pathway have undergone rigorous comparative assess-
ments to show similarity to a licensed biologic at all stages of the
development process, including in a clinical study or studies. In
contrast, oncologists should be aware of “noncomparable bio-
therapeutic products,” also known as “intended copies,” that have
been introduced as biosimilars in some countries (eg, Russia, China,
and India) where stringent regulatory pathways for biosimilar
approval had not yet been established or were under development at
the time these agents were approved.66-68 Intended copies are not
truly biosimilars in the context of this review or widely accepted
regulatory perspectives, because they have not met EMA, FDA, or
WHO requirements for establishing biosimilarity.67 In other words,
regulatory approval for intended copies did not follow a comparative
development pathway with the reference biologic and/or the sci-
entiﬁc and clinical evidence used to support the approval is
incomplete or absent.67 Therefore, intended copies might representa risk to patient safety and drug efﬁcacy because the quality and
clinical proﬁle of these products have not been as fully characterized
as would be a true biosimilar.
A “similar biologic” was approved by the Drugs Controller
General of India in 2013 as a trastuzumab biosimilar and is mar-
keted under the brand name CanMAb (Biocon Ltd, Bengaluru,
India), but this product should be considered an intended copy
because it was not evaluated using strict criteria for showing bio-
similarity to originator trastuzumab.69 The WHO has issued rec-
ommendations for regulatory risk assessment of biologic products
licensed following a generic pathway or with limited analytical,
nonclinical, and/or clinical evidence.70 These guidelines might help
address concerns regarding the safety and efﬁcacy of intended
copies.
Current Development Status of
Biosimilar Trastuzumab
Several trastuzumab biosimilars are in development and
comparative clinical PK studies in healthy volunteers have shown
pharmacologic equivalence and similar immunogenicity and safety
proﬁles between ABP 980 (Amgen, Thousand Oaks, CA),
Hercules/Myl-1401O (Mylan NV, Canonsburg, PA), PF-
05280014 (Pﬁzer Inc, New York, NY), and SB3 (Samsung Bio-
epis Co, Incheon, South Korea) and their respective trastuzumab
reference products.61,71-74 Comparative clinical studies have also
shown PK similarity of BCD-022 (Biocad, Saint-Petersburg, Russia)Clinical Breast Cancer April 2018 - 103
Figure 2 Examples of Analytical, Functional, and Nonclinical Data to Show Biosimilarity Between a Proposed Biosimilar and
Originator Biologic Product. (A) Peptide Map Proﬁles of PF-05280014, Trastuzumab-EU, and Trastuzumab-US. (B) Tumor Cell
Proliferation Inhibition Assay. Functional Similarity of PF-05280014, Trastuzumab-EU, and Trastuzumab-US Was Determined
Using an In Vitro Tumor Cell Proliferation Inhibition Assay (CellTiter Glo; Promega, Inc, Madison, WI) With a HER2-
Overexpressing Metastatic Breast Carcinoma Cell Line. (C) Individual and Mean ± SD Serum Concentration-Time Proﬁles of
PF-05280014, Trastuzumab-EU, and Trastuzumab-US After a Single Dose of 6 mg/kg in Healthy Subjects
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104 -and CT-P6 (Celltrion, Incheon, South Korea), each given in
combination with paclitaxel, to originator trastuzumab, also in
combination with paclitaxel, in patients with HER2þ MBC.75,76
Clinical trials comparing safety and efﬁcacy of these proposed or
approved trastuzumab biosimilars in patients with EBC or MBC are
ongoing (Table 3).77-100 Primary end points include measures of
tumor response, such as pCR in the neoadjuvant setting and ORR
in the metastatic setting. Secondary end points vary, but includeClinical Breast Cancer April 2018additional measures of efﬁcacy, such as event-free, progression-free,
and overall survival, as well as measures of safety and immunoge-
nicity (ie, antidrug and neutralizing antibodies).
To date, results from some of these trials have only been disclosed
at international oncology congresses.78,82,84,94,95,98,99 A study in
patients with HER2þ EBC comparing neoadjuvant treatment with
the proposed trastuzumab biosimilar ABP 980 and originator tras-
tuzumab, each after run-in anthracycline-based chemotherapy,
Table 3 Proposed Biosimilars of Trastuzumab With Registered Phase III Clinical Trials for Breast Cancer
Biosimilar
(Manufacturer),
Brand Name
(if approved)
Patient
Population
(Setting) Intervention
Primary End
Points
Secondary and
Other End Points
ClinicaTrials.Gov
Identiﬁer
Key Efﬁcacy and Safety Results
(Where Available)
Regulatory Filing Status
(If Known)
ABP 980 (Amgen,
Thousand Oaks,
CA)77,78
HER2þ EBC
(neoadjuvant and
adjuvant)
Epi and Cy/
ABP 980 and Pac
pCR EFS, OS, LVEF, AEs,
ADA, NAb
NCT01901146 pCR, local review: 48.0%
pCR, central independent review: 47.8%
1 AE: 80.2%
Grade 3þ AE: 14.8%
Most common AEs were arthralgia (17.3%), asthenia
(14.8%), neutropenia (14.6%), peripheral neuropathy
(13.7%)
and anemia (11.0%)
Submitted to EMA, 201779;
submitted to FDA, 201780
Epi and Cy/ Trast
and Pac
pCR, local review: 40.5%
RD (90% CI): 7.3% (1.2%-13.4%)a
RR (90% CI): 1.19 (1.033-1.366)a
pCR, central independent review: 41.8%
RD (90% CI): 5.8% (0.5% to 12.0%)b
RR (90% CI): 1.14 (0.993-1.312)b
1 AE: 79.5%
Grade 3þ AE: 14.1%
Most common AEs were arthralgia (15.2%), asthenia (16.3%),
neutropenia (12.5%), peripheral neuropathy (11.9%),
and anemia (10.2%)
BCD-022 (Biocad,
Saint-Petersburg,
Russia)81,82
HER2þ MBC
(ﬁrst-line)
BCD-022 and Pac ORR, PK CR, PR, stabilization
rate, progression rate,
AEs, CTX cycles
postponed because of
AEs, DC due to AEs,
ADA, PK
NCT01764022 ORR (95% CI): 53.57% (40.70-65.98)
CR: 5.36%
PR: 48.21%
SD: 25.0%
Progression rate: 21.43%
NAb: 1 patient
Trast and Pac ORR (95% CI): 53.70% (40.60-66.31)
CR: 3.70%
PR: 50.0%
SD: 25.93%
Progression rate: 20.37%
NAb: 1 patient
Lower limit of 95% CI for ORR difference between groups
(19.83%) did not exceed the noninferiority margin
No statistically signiﬁcant differences between groups for all
other efﬁcacy end points, or in rate of AEs (including
severe AEs)
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Table 3 Continued
Biosimilar
(Manufacturer),
Brand Name
(if approved)
Patient
Population
(Setting) Intervention
Primary End
Points
Secondary and
Other End Points
ClinicaTrials.Gov
Identiﬁer
Key Efﬁcacy and Safety Results
(Where Available)
Regulatory Filing Status
(If Known)
CT-P6 (Celltrion
Incheon, South
Korea),
Herzuma
83-86
HER2
þ EBC
(neoadjuvant and
adjuvant)
CT-P6 and Doc/
CT-P6 and F and Epi
and Cy
pCR ORR, PK, PD, and
safety
NCT02162667 pCR (95% CI): 46.8% (40.4-53.2)
ORR (95% CI): 88.3% (83.6-92.0)
1 SAE: 7.4%
Withdrew treatment because of signiﬁcant LVEF decrease:
3 patients
IRR: 11.4%
Approved by EMA, 201887;
submitted to MHLW in Japan,
201788; submitted to FDA,
201780
Trast and Doc/
Trast and F and Epi
and Cy
pCR (95% CI): 50.4% (44.1-56.7)
ORR (95% CI): 89.5% (85.0-92.9)
1 Treatment-emergent SAE: 11.9%
Withdrew treatment because of signiﬁcant LVEF decrease:
3 patients
IRR: 10.4%
pCR treatment difference (95% CI): 0.0362
(0.1238 to 0.0516)c
ORR treatment difference (95% CI): 0.0115
(0.0990 to 0.0764)
HER2þ MBC CT-P6 and Pac ORR Safety and efﬁcacy NCT01084876 ORR: 57%
Median TTP: 11.07 mo
Median TTR: 1.38 mo
SAEs: 13.5%
IRR: 15.6%
Cardiotoxicity: 3.3%
Trast and Pac ORR: 62%
Median TTP: 12.52 mo
Median TTR: 1.38 mo
SAEs: 12.1%
IRR: 26.0%
Cardiotoxicity: 4.3%
ORR treatment difference (95% CI): 5% (e0.14 to 0.04)c
TTP; P ¼ .10
TTR; P ¼ .37
Hercules/Myl-
1401O (Biocon,
Bengaluru,
India/Mylan,
Canonsburg, PA),
Ogivri89
HER2þ MBC (ﬁrst-line) Hercules/Myl-1401O
and Pac or Doc
24-Week ORR Secondary: TTP, PFS,
and OS at 48 weeks;
Other: AEs, laboratory
assessments, LVEF,
immunogenicity
NCT02472964 24-Week ORR (95% CI): 69.6% (63.62-75.51)
48-Week PFS: 44.3%
48-Week OS: 89.1%
TEAE: 96.8%
ADA: 2.4%
Application resubmitted to
EMA, 201790; approved by
FDA, 201791
Trast and Pac or Doc 24-Week ORR (95% CI): 64.0% (57.81-70.26)
48-Week PFS: 44.7%
48-Week OS: 85.1%
TEAE: 94.7%
ADA: 2.8%
ORR ratio (90% CI): 1.09 (0.974-1.211)d
ORR difference (95% CI): 5.53 (3.08 to 14.04)e
PFS difference (95% CI): 0.4% (9.4 to 8.7; P ¼ .84)f
OS difference (95% CI): 4.0% (2.1 to 10.3; P ¼ .13)f
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Biosimilar
(Manufacturer),
Brand Name
(if approved)
Patient
Population
(Setting) Intervention
Primary End
Points
Secondary and
Other End Points
ClinicaTrials.Gov
Identiﬁer
Key Efﬁcacy and Safety Results
(Where Available)
Regulatory Filing Status
(If Known)
PF-05280014
(Pﬁzer, New York,
NY)92-95
HER2þ MBC
(ﬁrst-line)
PF-05280014
and Pac
ORR DOR, 1-year PFS rate,
1-year OS rate, safety,
PK, ADA, NAb
NCT01989676 1-Year PFS: 56%
1-Year OS: 88.84%
ADA: 0 patients
Submitted to EMA, 2017;
submitted to FDA, 201796
Trast-EU and Pac RR for ORR (95% CI): 0.940 (0.842-1.049)g
1-Year PFS: 52%
1-Year OS: 87.96%
ADA: 1 patient
Safety proﬁle, including incidence of SAEs, was similar between
arms, and no new safety signals were identiﬁed
Mean trough and peak serum concentrations were similar
for both agents, up to cycle 5 day 8
HER2þ EBC
(neoadjuvant)
PF-05280014 and
Doc/Carb
PK pCR, safety, ADA, NAb,
PK, ORR
NCT02187744 Patients with cycle 5 Ctrough (pre-dose cycle 6)
>20mg/mL: 92.1%
pCR (95% CI): 47.0% (36.9%-57.2%)
ORR (95% CI): 88.1% (80.2%-93.7%)
All-causality, Grade 3-4 TEAEs: 38.1%
ADA: 0%
Trast-EU and
Doc/Carb
Patients with cycle 5 Ctrough (pre-dose cycle 6)>20mg/mL: 93.3%
95% CI for stratiﬁed difference: 8.02% to 6.49%h
pCR (95% CI): 50.0% (39.0%-61.0%)
ORR (95% CI): 82.0% (72.5%-89.4%)
All-causality, Grade 3-4 TEAEs: 45.5%
ADA: 0.89%
SB3 (Samsung
Bioepis, Incheon,
South Korea),
Ontruzant97-99
HER2þ BC
(neoadjuvant)
SB3 and Doc/ F
and Epi and Cy
bpCR tpCR, ORR, EFS, OS,
PK, immunogenicity,
safety
NCT02149524 Neoadjuvant period:
bpCR: 51.7%
tpCR: 45.8%
ORR: 96.3%
TEAE: 96.6%
SAE: 10.5%
Adjuvant period (1 year):
TEAEs: 97.5%
Grade 3þ TEAEs: 74.3%
TEAEs of special interest: 11.0%i
SAEs: 12.8%
Deaths: 0.2%
ADA: 0.7%
Approved by EMA, 2017;
submitted to FDA, 2017100
Trast and Doc/ F
and Epi and Cy
Neoadjuvant period: bpCR: 42.0%
tpCR: 35.8%
ORR: 91.2%
TEAE: 95.2%
SAE: 10.7%
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Biosimilar
(Manufacturer),
Brand Name
(if approved)
Patient
Population
(Setting) Intervention
Primary End
Points
Secondary and
Other End Points
ClinicaTrials.Gov
Identiﬁer
Key Efﬁcacy and Safety Results
(Where Available)
Regulatory Filing Status
(If Known)
bpCR ratio (90% CI): 1.259 (1.112-1.426)j
bpCR difference (95% CI): 10.70% (4.13-17.26)j
PK equivalence was shown
Immunogenicity was comparable (0.7% vs. 0%) between SB3
and Trast groups, respectively
Adjuvant period:
TEAEs: 96.1%
Grade 3þ TEAEs: 71.9%
TEAEs of special interest: 12.1%i
SAEs: 13.2%
Deaths: 1.1%
ADA: 0.7%
Abbreviations: ADA ¼ antidrug antibodies; AE ¼ adverse event; BC ¼ breast cancer; bpCR ¼ breast pathologic complete response; Carb ¼ carboplatin; CI ¼ conﬁdence interval; CR ¼ complete response; Ctrough ¼ trough plasma concentration (at end of dosing interval at
steady-state); CTX ¼ chemotherapy; Cy ¼ cyclophosphamide; DC ¼ discontinued; DFS ¼ disease-free survival; Doc ¼ docetaxel; DOR ¼ duration of response; EBC ¼ early breast cancer; EFS ¼ event-free survival; EMA ¼ European Medicines Agency; Epi ¼ epirubicin; F ¼
5-ﬂuorouracil; FDA ¼ US Food and Drug Administration; IRR ¼ infusion-related reactions; LVEF ¼ left ventricular ejection fraction; MBC ¼ metastatic breast cancer; MHLW ¼ Ministry of Health, Labor and Welfare; NAb ¼ neutralizing antibodies; ORR ¼ overall response rate;
OS ¼ overall survival; Pac ¼ paclitaxel; pCR ¼ pathological complete response; PFS ¼ progression-free survival; PK ¼ pharmacokinetics; PR ¼ partial response; RD ¼ risk difference; RR ¼ risk ratio; SAE ¼ serious adverse event; SD ¼ stable disease; TEAE ¼ treatment-
emergent adverse event; tpCR ¼ total pathological complete response; Trast ¼ trastuzumab; Trast-EU ¼ trastuzumab sourced from the European Union; TTP ¼ time to progression; TTR ¼ time to response.
aThe upper bound of the 90% CIs for RD and RR of pCR slightly exceeded the equivalence margins (13.0% and 0.759-1.318, respectively).
bThe 2-sided 90% CIs for RD and RR of pCR were contained within the equivalence margins (13.0% and 0.759-1.318, respectively).
cThe 95% CI for the treatment difference was within the equivalence margin (0.15).
dThe 90% CI was within the predeﬁned equivalence margin (0.81%-1.24%), consistent with statistical therapeutic equivalence of Hercules/Myl-1401O and Trast.
eThe 95% CI was within the predeﬁned equivalence margin (15%), consistent with statistical therapeutic equivalence of Hercules/Myl-1401O and Trast, per EMA recommendation.
fNo statistically signiﬁcant difference in PFS or OS was observed between treatment groups.
gThe 95% CI for RR of ORR was within the prespeciﬁed equivalence margin of 0.8 to 1.25.
hThe lower limit of the 95% CI for the stratiﬁed difference between groups was above the noninferiority margin (12.5%).
iIncludes IRR, left ventricular systolic dysfunction, and congestive heart failure.
jThe 90% CI for the ratio of bpCR was within the prespeciﬁed equivalence margin (0.785-1.546); the lower margin of the 95% CI for the difference between bpCR rates was contained within and the upper margin was outside of the predeﬁned equivalence margin (13%).
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Kimberly Blackwell et alshowed clinical equivalence between the 2 products on the basis of
central independent review of pCR (47.8% and 41.8%, respec-
tively), and comparable safety proﬁles, with 292 (80.2%) and 287
(79.5%) patients, respectively, reporting 1 or more adverse events.78
The efﬁcacy and safety of neoadjuvant CT-P6 and originator tras-
tuzumab, each in combination with chemotherapy, were compared
in patients with HER2þ EBC.84 The pCR rate was 46.8% for CT-
P6 and 50.4% for originator trastuzumab, and the 95% CI
(0.1238 to 0.0516) for the estimate of treatment difference
(0.0362) was within the equivalence margin (0.15), showing
equivalence in efﬁcacy between the 2 treatments.84 CT-P6 and
originator trastuzumab also had similar safety proﬁles (7.4% vs.
11.9% of patients, respectively, reported 1 serious adverse
event).84 In a study conducted in patients with HER2þ MBC, the
proposed trastuzumab biosimilar BCD-022 showed noninferiority
in efﬁcacy to originator trastuzumab on the basis of ORRs of
53.57% and 53.70%, respectively.82
Two studies have compared the proposed trastuzumab biosimilar
PF-05280014 and originator trastuzumab sourced from the Euro-
pean Union (trastuzumab-EU) in patients with HER2þ MBC or
EBC.94,95 A comparative safety and efﬁcacy study of PF-05280014
versus originator trastuzumab, each in combination with paclitaxel
as ﬁrst-line treatment for HER2þ MBC, showed equivalence in the
primary end point of ORR, with the 95% CI (0.842-1.049) for the
risk ratio for ORR (0.940 for PF-05280014/trastuzumab-EU) be-
ing within the prespeciﬁed equivalence margin (0.80-1.25).95 Rates
of progression-free survival (56% for PF-05280014 vs. 52% for
trastuzumab-EU) and overall survival (88.84% vs. 87.96%) at
1 year, as well as the safety proﬁles were also similar between
groups.95 A separate comparative PK trial of PF-05280014 versus
originator trastuzumab, each in combination with docetaxel and
carboplatin, in patients with HER2þ EBC also met its primary end
point, showing noninferiority of PF-05280014 to trastuzumab-EU
in the proportion of patients with cycle 5 trough plasma concen-
tration (pre-dose cycle 6) >20 mg/mL (92.1% vs. 93.3%, respec-
tively).94 Rates of pCR (47.0% for PF-05280014 vs. 50.0% for
trastuzumab-EU) and ORR (88.1% vs. 82.0%), as well as incidence
of all-causality Grade 3/4 treatment-emergent adverse events
(38.1% vs. 45.5%), were also similar between groups.94
The trastuzumab biosimilar SB3 and originator trastuzumab,
each given with chemotherapy, were compared as neoadjuvant
treatment for HER2þ EBC.98,99 Results showed equivalence in
efﬁcacy between treatments on the basis of the ratio of breast pCR
(1.259; 51.7% for SB3 vs. 42.0% for originator trastuzumab), for
which the 90% CI (1.112-1.426) was within the predeﬁned
equivalence margin (0.785-1.546).98 Furthermore, 1-year safety,
immunogenicity, and survival proﬁles were also similar between
SB3 and originator trastuzumab.99
Published data from a study in patients with HER2þ MBC
showed comparability between CT-P6 and trastuzumab, each
treatment in combination with paclitaxel, with respect to ORR and
the incidence of adverse events.86 Results from a trial comparing the
efﬁcacy of Hercules/Myl-1401O versus trastuzumab, each in com-
bination with paclitaxel or docetaxel, as ﬁrst-line treatment in pa-
tients with HER2þ MBC showed equivalence in efﬁcacy and
comparable safety (Table 3).89 Reported 24-week ORR was 69.6%
(160 patients) in the Hercules/Myl-1401O group and 64.0% (146patients) in the trastuzumab group, and the incidence of patients
with at least 1 treatment-emergent adverse event was 96.8% (239
patients) in the Hercules/Myl-1401O group and 94.7% (233 pa-
tients) in the trastuzumab group.89
An application for marketing authorization for ABP 980 was
submitted to the EMA and to the FDA.79,80 A marketing autho-
rization application for CT-P6 was approved by the EMA, and
submitted to the Ministry of Health, Labor and Welfare in Japan,
and to the FDA.80,87,88 A resubmitted application for marketing
authorization for Hercules/Myl-1401O was accepted for review by
the EMA; an application for marketing authorization for Hercules/
Myl-1401O was approved by the FDA.90,91 A marketing authori-
zation application for PF-05280014 was submitted to the EMA and
to the FDA.96 Finally, a marketing authorization application for
SB3 was approved by the EMA, and an application for marketing
authorization for SB3 was submitted to the FDA.100
Economic Effect of Biosimilars
The regulatory framework for biosimilars provides a more
tailored pathway for approval compared with originator biologics
that relies on a rigorous assessment of similarity. As a result, bio-
similars might provide a lower-cost alternative to originator bi-
ologics and have the potential to generate cost savings. Anticipated
pricing for biosimilars is approximately 20% to 30% lower than
originator biologics.101 Recent studies of biosimilar pricing in
Europe reported discounts generally ranging from 5% to 35% over
originator biologics, although discounts of up to 75% were noted in
some cases.102-105 In general, price discounts for biosimilars might
be considered modest compared with small-molecule generics,
which can be priced 80% to 90% lower than the brand-name
counterpart.101-105 This difference is explained in part by the
greater complexity of biosimilars in terms of their structure and
manufacturing process compared with chemically synthesized,
small-molecule generics, which leads to higher development costs
($100-$200 million vs. $1-$5 million) and longer development
timelines (8-10 years vs. 3-5 years).101
A 2016 report estimated the introduction of biosimilars to
generate cumulative potential savings of V49 billion (20% dis-
count) to V98 billion (40% discount) in France, Germany, Italy,
Spain, the United Kingdom, and the United States between 2016
and 2020.106 Pharmacoeconomic evaluations have been conducted
for different biosimilars to estimate their potential savings and effect
in different countries. To date, only 1 budget impact analysis has
been conducted for biosimilar trastuzumab.107 In this analysis
introduction of trastuzumab biosimilars in Croatia was estimated to
generate potential savings varying from V0.26 million (15% price
discount) to V0.69 million (35% price discount) that could be
reinvested to treat an additional 14 (15% price discount) to 47
(35% price discount) patients.107
The extent of cost savings achieved with biosimilars will depend
on many factors; thus, drug price in and of itself is not sufﬁcient to
understand the potential savings.106,108,109 An important consid-
eration will be future trends in biologic drug utilization.109 Tras-
tuzumab was ﬁrst introduced as an intravenous formulation,3,4 but
in 2013 a subcutaneous formulation was approved by the EMA for
treatment of early or metastatic HER2þ breast cancer.110 Subcu-
taneous trastuzumab has shown noninferiority in PK and efﬁcacyClinical Breast Cancer April 2018 - 109
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110 -and a safety proﬁle that is similar to intravenous trastuzumab.111-114
Furthermore, subcutaneous trastuzumab is administered over a
shorter period of time than intravenous trastuzumab (5 minutes vs.
30-90 minutes) and might be preferred by patients.4,113 Trastuzu-
mab biosimilars might provide a lower-cost alternative to originator
trastuzumab. However, in many institutions this price reduction for
biosimilars might be outweighed by savings associated with use of
subcutaneous administration of originator trastuzumab, especially
because budgets for drug purchase, pharmacy, and the chemo-
therapy suite might be independent and held separately.
The potential effect of biosimilars on health care budgets and
patient access to biologic therapy is signiﬁcant, including in coun-
tries where cost is already a major issue. For example, 53%, 63%,
and 81% of physicians surveyed in the countries of Brazil, Mexico,
and Russia reported they would increase the use of HER2 therapy
for treatment of HER2þ breast cancer if a lower cost trastuzumab
biosimilar was available.21 In addition, with current drug pricing
trastuzumab is not considered cost-effective in several Latin Amer-
ican countries.53 However, introduction of a lower-cost biosimilar
to this region could make trastuzumab cost-effective and support
decisions for drug funding and reimbursement, thereby improving
patient access to HER2 therapy for treatment of HER2þ breast
cancer. Finally, many low-income countries rely on the WHO
Model List of Essential Medicines to select or prioritize drugs for
national essential or reimbursable medicine lists.115 The WHO has
initiated a pilot program, inviting manufacturers to submit appli-
cations for prequaliﬁcation of rituximab and trastuzumab bio-
similars into their Essential Medicines List.116 Accordingly,
implementation of this program might improve patient access to
HER2 therapy for treatment of HER2þ breast cancer.
Conclusions
Trastuzumab is standard treatment for HER2þ breast cancer, but
access to this drug remains limited even in some developed coun-
tries. Biosimilars offer an approach to expand access to biologic
therapies by placing additional highly similar, high-quality products
into clinical practice. In oncology practice, the ﬁrst approved bio-
similars (eg, epoetin and ﬁlgrastim) are used in supportive care, and
have clinical effects that can be quickly and easily measured.
Furthermore, extensive and required postapproval pharmacovigi-
lance programs are in place to monitor for additional safety signals.
This has provided clinicians with assurance about the safety and
efﬁcacy of these biosimilars. Monoclonal antibodies such as tras-
tuzumab as anticancer drugs have effects on patient outcomes that
are not as easily assessed. Understanding the scientiﬁc and regula-
tory aspects of biosimilar development will help clinicians be
comfortable using a trastuzumab biosimilar across all clinical
settings.
Trastuzumab biosimilars are in development and might soon
become available. The availability of safe and effective trastuzumab
biosimilars might help address the need for increased trastuzumab
access for patients with HER2þ breast cancer worldwide. It is likely
that trastuzumab biosimilars will be used in all indications for which
the originator is approved; therefore, in addition to patients treated
for breast cancer, patients with HER2þ metastatic gastric or
gastroesophageal junction adenocarcinoma might also beneﬁt from
the availability of trastuzumab biosimilars.Clinical Breast Cancer April 2018The introduction of trastuzumab biosimilars will be accompanied
by the expectation of cost savings, although, with a projected dis-
count of approximately 20% to 30%,101 the cost savings are
anticipated to be lower than with generic drugs. Nevertheless,
trastuzumab biosimilars might expand use of HER2-targeted and
other new therapies by generating savings for health care systems.
Furthermore, biosimilars might provide greater economic beneﬁts
in emerging markets,53 and other countries where cancer drugs are
less affordable.Acknowledgments
This review was supported by Pﬁzer Inc. Medical writing support
was provided by Elyse Smith, PhD, of Engage Scientiﬁc Solutions
and funded by Pﬁzer Inc.
Disclosure
Kimberly Blackwell has received consulting honoraria from
Genentech/Roche, Novartis, Pﬁzer Inc, and Sandoz. Joseph Gli-
gorov has received consulting honorarium from Eisai, Genentech/
Roche, Genomic Health, Novartis, and Pﬁzer Inc, and research
funding support from Eisai, Genentech/Roche, and Genomic
Health. Ira Jacobs is a full-time employee of and declares stock
holdings and/or stock options from Pﬁzer Inc. Chris Twelves has
received honoraria for serving on advisory boards for and received
speakers’ fees from Daiichi Sankyo, Eisai, Nektar, and Pﬁzer Inc.References
1. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical
signiﬁcance of HER-2/neu oncogene ampliﬁcation in primary breast cancer.
The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11:
1936-42.
2. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human
epidermal growth factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists Clinical Practice Guideline
update. J Clin Oncol 2013; 31:3997-4013.
3. Herceptin (trastuzumab) [US prescribing information]. South San Francisco, CA:
Genentech, Inc; 2017.
4. European Medicines Agency. Herceptin (trastuzumab) summary of product
characteristics, Available at: http://www.ema.europa.eu/docs/en_GB/
document_library/EPAR_-_Product_Information/human/000278/WC500074922.
pdf 2017. Accessed: April 3, 2017.
5. World Health Organization. WHO model list of essential medicines: 19th list,
Available at: http://www.who.int/medicines/publications/essentialmedicines/
EML_2015_FINAL_amended_NOV2015.pdf?ua¼1 2015. Accessed: April 3,
2017.
6. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international
consensus guidelines for advanced breast cancer (ABC2)dagger. Ann Oncol
2014; 25:1871-88.
7. Denduluri N, Somerﬁeld MR, Eisen A, et al. Selection of optimal adjuvant
chemotherapy regimens for early breast cancer and adjuvant targeted therapy for
human epidermal growth factor receptor 2epositive breast cancers: an American
Society of Clinical Oncology Guideline adaptation of the Cancer Care Ontario
Clinical Practice Guideline. J Clin Oncol 2016; 34:1-12.
8. Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with
advanced human epidermal growth factor receptor 2-positive breast cancer:
American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol
2014; 32:2078-99.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines
in Oncology: breast cancer, version 1.2016, Available at: https://www.nccn.org/
2016. Accessed: April 3, 2017.
10. Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;
26(suppl 5):v8-30.
11. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a
monoclonal antibody against HER2 for metastatic breast cancer that over-
expresses HER2. N Engl J Med 2001; 344:783-92.
12. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression
in human epidermal growth factor receptor 2-positive advanced breast cancer: a
German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol
2009; 27:1999-2006.
Kimberly Blackwell et al
13. Genetic Engineering & Biotechnology News (GEN). Philippidis A. Biosimilars:
11 drugs to watch, Available at: http://www.genengnews.com/the-lists/
biosimilars-11-drugs-to-watch/77900135?q¼biosimilars%2011%20drugs%20to
%20watch 2014. Accessed: April 3, 2016.
14. European Medicines Agency. Committee for Medicinal Products for Human Use
(CHMP). Guideline on similar biological medicinal products, Available at: http://
www.ema.europa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/2014/1
0/WC500176768.pdf 2014. Accessed: April 3, 2017.
15. US Food and Drug Administration. Scientiﬁc considerations in demonstrating
biosimilarity to a reference product. Guidance for industry, Available at: http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM291128.pdf 2015. Accessed: April 3, 2017.
16. World Health Organization. Guidelines on evaluation of similar biotherapeutic
products (SBPs), Available at: http://www.who.int/biologicals/areas/biological_
therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf 2009.
Accessed: April 3, 2017.
17. Gascon P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio in Europe:
what have we learned? Support Care Cancer 2013; 21:2925-32.
18. Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia
management with biosimilar epoetin alfa and increased access to targeted anti-
neoplastic treatment: a simulation for the EU G5 countries. Future Oncol 2014;
10:1599-609.
19. Chavarri-Guerra Y, St Louis J, Bukowski A, et al. Real world patterns of care in
HER2-overexpressing breast cancer: results of a survey of TEACH Clinical Trial
Investigators in 2011. Breast 2017; 31:197-201.
20. Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European Consortium
Study on the availability, out-of-pocket costs and accessibility of antineoplastic
medicines in Europe. Ann Oncol 2016; 27:1423-43.
21. Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the use of tras-
tuzumab for HER2þ breast cancer and the potential impact of biosimilars: a
physician survey in the United States and emerging markets. Pharmaceuticals
(Basel) 2014; 7:943-53.
22. Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in
patients with HER2-positive metastatic breast cancer: incidence, treatment, and
survival in patients from registHER. Clin Cancer Res 2011; 17:4834-43.
23. Coulson SG, Kumar VS, Manifold IM, et al. Review of testing and use of
adjuvant trastuzumab across a cancer networkeare we treating the right patients?
Clin Oncol (R Coll Radiol) 2010; 22:289-93.
24. DaCosta Byﬁeld S, Buck PO, Blauer-Peterson C, Poston SA. ReCAP: treatment
patterns and cost of care associated with initial therapy among patients diagnosed
with operable early-stage human epidermal growth factor receptor
2-overexpressed breast cancer in the United States: a real-world retrospective
study. J Oncol Pract 2016; 12:159-60.
25. de Munck L, Schaapveld M, Siesling S, et al. Implementation of trastuzumab in
conjunction with adjuvant chemotherapy in the treatment of non-metastatic
breast cancer in the Netherlands. Breast Cancer Res Treat 2011; 129:229-33.
26. DeKoven M, Bonthapally V, Jiao X, et al. Treatment pattern by hormone
receptors and HER2 status in patients with metastatic breast cancer in the UK,
Germany, France, Spain and Italy (EU-5): results from a physician survey. J Comp
Eff Res 2012; 1:453-63.
27. Gao S, Barber B, Schabert V, Ferruﬁno C. Tumor hormone/HER2 receptor
status and pharmacologic treatment of metastatic breast cancer in Western
Europe. Curr Med Res Opin 2012; 28:1111-8.
28. Gori S, Inno A, Fiorio E, et al. The Promher Study: an observational Italian study
on adjuvant therapy for HER2-positive, pT1a-b pN0 breast cancer. PLoS One
2015; 10:e0136731.
29. Kaufman PA, Brufsky AM, Mayer M, et al. Treatment patterns and clinical
outcomes in elderly patients with HER2-positive metastatic breast cancer from
the registHER observational study. Breast Cancer Res Treat 2012; 135:875-83.
30. Kurian AW, Lichtensztajn DY, Keegan TH, et al. Patterns and predictors of
breast cancer chemotherapy use in Kaiser Permanente Northern California,
2004-2007. Breast Cancer Res Treat 2013; 137:247-60.
31. Liebrich C, Unger G, Dlugosch B, Hofmann S, Petry KU. Adopting guidelines
into clinical practice: implementation of trastuzumab in the adjuvant treatment of
breast cancer in Lower Saxony, Germany, in 2007. Breast Care (Basel) 2011; 6:
43-50.
32. Noonan KL, McCarthy J, Powell E, Laing K, Edwards S, McCrate F.
A population-based analysis of patients with early-stage HER2-positive breast
cancer in Newfoundland and Labrador. Oncol Exchange 2012; 11:14-9.
33. Patt DA, Fonseca E, Yoo B, Wilson T, Goertz HP, Lai C. Real-world treatment
patterns and outcomes in HER2 positive MBC patients with brain metastasis in
the U.S. community oncology setting. J Clin Oncol 2016; 34 (abstract 92).
34. Peters E, Anzeneder T, Jackisch C, et al. The treatment of primary breast cancer
in older women with adjuvant therapy: a retrospective analysis of data from over
3000 patients from the PATH Biobank, with two-year follow-up. Dtsch Arztebl
Int 2015; 112:577-84.
35. Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Dis-
parities in use of human epidermal growth hormone receptor 2-targeted therapy
for early-stage breast cancer. J Clin Oncol 2016; 34:2003-9.
36. Seferina SC, Lobbezoo DJ, de Boer M, et al. Real-life use and effectiveness of
adjuvant trastuzumab in early breast cancer patients: a study of the Southeast
Netherlands Breast Cancer Consortium. Oncologist 2015; 20:856-63.
37. Stenehjem DD, Yoo M, Unni SK, et al. Assessment of HER2 testing patterns,
HER2þ disease, and the utilization of HER2-directed therapy in early breast
cancer. Breast Cancer (Dove Med Press) 2014; 6:169-77.38. Tripathy D, Kaufman PA, Brufsky AM, et al. First-line treatment patterns and
clinical outcomes in patients with HER2-positive and hormone receptor-positive
metastatic breast cancer from registHER. Oncologist 2013; 18:501-10.
39. Vaz-Luis I, Lin NU, Keating NL, et al. Treatment of early-stage human
epidermal growth factor 2-positive cancers among medicare enrollees: age and
race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat
2016; 159:151-62.
40. Webster RM, Abraham J, Palaniappan N, Caley A, Jasani B, Barrett-Lee P.
Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast
cancer patients in a large UK cancer network. Do the results of international
clinical trials translate into a similar beneﬁt for patients in South East Wales? Br J
Cancer 2012; 106:32-8.
41. Whitﬁeld R, Kollias J, De Silva P, Zorbas H, Maddern G. Use of trastuzumab in
Australia and New Zealand: results from the National Breast Cancer Audit. ANZ
J Surg 2012; 82:234-9.
42. Wilking U, Jonsson B, Wilking N, Bergh J. Trastuzumab use in breast cancer
patients in the six health care regions in Sweden. Acta Oncol 2010; 49:844-50.
43. Yardley DA, Kaufman PA, Brufsky A, et al. Treatment patterns and clinical
outcomes for patients with de novo versus recurrent HER2-positive metastatic
breast cancer. Breast Cancer Res Treat 2014; 145:725-34.
44. Zurawska U, Baribeau DA, Giilck S, et al. Outcomes of HER2-positive early-
stage breast cancer in the trastuzumab era: a population-based study of Cana-
dian patients. Curr Oncol 2013; 20:e539-45.
45. Li J, Wang S, Wang Y, et al. Disparities of trastuzumab use in resource-limited or
resource-abundant regions and its survival beneﬁt on HER2 positive breast
cancer: a real-world study from China. Oncologist 2017; 22:1333-8.
46. Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus
lapatinib plus capecitabine in patients with HER2-positive metastatic breast
cancer and central nervous system metastases: a retrospective, exploratory analysis
in EMILIA. Ann Oncol 2015; 26:113-9.
47. Cortes J, Rugo HS, Awada A, et al. Prolonged survival in patients with breast
cancer and a history of brain metastases: results of a preplanned subgroup analysis
from the randomized phase III BEACON trial. Breast Cancer Res Treat 2017;
165:329-41.
48. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive
heart failure in older women treated with adjuvant anthracycline chemotherapy
for breast cancer. J Clin Oncol 2007; 25:3808-15.
49. Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. Inter-
national variability in the reimbursement of cancer drugs by publically funded
drug programs. Curr Oncol 2012; 19:e165-76.
50. Hall PS, Hulme C, McCabe C, Oluboyede Y, Round J, Cameron DA. Updated
cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective
considering duration of beneﬁt, long-term toxicity and pattern of recurrence.
Pharmacoeconomics 2011; 29:415-32.
51. Hedden L, O’Reilly S, Lohrisch C, et al. Assessing the real-world cost-effec-
tiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist
2012; 17:164-71.
52. Leung W, Kvizhinadze G, Nair N, Blakely T. Adjuvant trastuzumab in HER2-
positive early breast cancer by age and hormone receptor status: a cost-utility
analysis. PLoS Med 2016; 13:e1002067.
53. Pichon-Riviere A, Garay OU, Augustovski F, et al. Implications of global pricing
policies on access to innovative drugs: the case of trastuzumab in seven Latin
American countries. Int J Technol Assess Health Care 2015; 31:2-11.
54. Garattini L, van de Vooren K, Curto A. Cost-effectiveness of trastuzumab in
metastatic breast cancer: mainly a matter of price in the EU? Health Policy 2015;
119:212-6.
55. Diaby V, Adunlin G, Ali AA, et al. Cost-effectiveness analysis of 1st through 3rd
line sequential targeted therapy in HER2-positive metastatic breast cancer in the
United States. Breast Cancer Res Treat 2016; 160:187-96.
56. Crommelin D, Bermejo T, Bissig M, et al. Pharmaceutical evaluation of bio-
similars: important differences from generic low-molecular-weight pharmaceuti-
cals. Eur J Hosp Pharm Sci 2005; 11:7.
57. Azevedo V, Hassett B, Fonseca JE, et al. Differentiating biosimilarity and
comparability in biotherapeutics. Clin Rheumatol 2016; 35:2877-86.
58. Kozlowski S. Biosimilar biological products: overview of approval pathway under
the biologics price competition and innovation act of 2009, Available at: https://c.
ymcdn.com/sites/casss.site-ym.com/resource/resmgr/WCBP_Speaker_Slides/2013
_WCBP_Kozlowski_Steven.pdf 2013. Accessed: April 3, 2017.
59. European Medicines Agency. Committee for Medicinal Products for Human Use
(CHMP). Guideline on similar biological medicinal products containing
biotechnology-derived proteins as active substance: non-clinical and clinical is-
sues, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/
Scientiﬁc_guideline/2015/01/WC500180219.pdf 2014. Accessed: April 3, 2017.
60. US Congress. The biologics price competition and innovation act of 2009. Public
law 111-148, Section 7001-7003, Available at: https://www.gpo.gov/fdsys/pkg/
STATUTE-124/pdf/STATUTE-124-Pg119.pdf 2010. Accessed: April 3, 2017.
61. Yin D, Barker KB, Li R, et al. A randomized phase 1 pharmacokinetic
trial comparing the potential biosimilar PF-05280014 with trastuzumab in
healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol 2014; 78:
1281-90.
62. Hurst S, Ryan AM, Ng CK, et al. Comparative nonclinical assessments of the
proposed biosimilar PF-05280014 and trastuzumab (Herceptin). BioDrugs 2014;
28:451-9.
63. European Medicines Agency. Committee for Medicinal Products for Human Use
(CHMP). Guideline on similar biological medicinal products containingClinical Breast Cancer April 2018 - 111
Need for Trastuzumab Biosimilar for HER2-Positive Breast Cancer
112 -monoclonal antibodies e non-clinical and clinical issues, Available at: http://
www.ema.europa.eu/docs/en_GB/document_library/Scientiﬁc_guideline/2012/0
6/WC500128686.pdf 2012. Accessed: April 4, 2017.
64. Isakov L, Jin B, Jacobs IA. Statistical primer on biosimilar clinical development.
Am J Ther 2016; 23:e1903-10.
65. US Food and Drug Administration. Guidance for industry: bioavailability and
bioequivalence studies for orally administered drug products — general consid-
erations, Available at: http://www.fda.gov/ohrms/dockets/ac/03/brieﬁng/
3995B1_07_GFI-BioAvail-BioEquiv.pdf 2003. Accessed: March 24, 2016.
66. Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations
for biosimilar oncology drugs. Lancet Oncol 2014; 15:e594-605.
67. Mysler E, Pineda C, Horiuchi T, et al. Clinical and regulatory perspectives on
biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol
Int 2016; 36:613-25.
68. International Federation of Pharmaceutical Manufacturers & Associations. Policy
statement. Non-comparable biotherapeutic products, Available at: http://www.
ifpma.org/wp-content/uploads/2016/02/Non-comparable_Biotherapeutic_
Products__English__02.pdf 2014. Accessed: April 3, 2017.
69. Generics and Biosimilars Initiative. Biosimilars of trastuzumab, Available at:
http://www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab 2017.
Accessed: April 4, 2017.
70. World Health Organization. Regulatory assessment of approved rDNA-derived
biotherapeutics. Proposed addendum to: WHO TRS 987, Annex 4. Guidelines
on the quality, safety and efﬁcacy of biotherapeutic protein products prepared by
recombinant DNA technology, Available at: http://www.who.int/biologicals/RA_
for_BTP_for_WHO_web_editor_2_Nov_2015(2).pdf 2015. Accessed: October
20, 2017.
71. Pivot X, Curtit E, Lee YJ, et al. A randomized phase I pharmacokinetic study
comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects.
Clin Ther 2016; 38:1665-73.
72. Waller CF, Vutikullird A, Lawrence TE, et al. A pharmacokinetics (PK) bio-
equivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs
EU-Herceptin (B) and US-Herceptin (C). J Clin Oncol 2016; 34 (abstract 583).
73. Wisman LA, De Cock EP, Reijers JA, et al. A phase I dose-escalation and bio-
equivalence study of a trastuzumab biosimilar in healthy male volunteers. Clin
Drug Investig 2014; 34:887-94.
74. Hanes V, Chow V, Zhang N, Markus R. A randomized, single-blind, single-dose
study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP
980 and trastuzumab in healthy male subjects. Cancer Chemother Pharmacol
2017; 79:881-8.
75. Im YH, Krasnozhon D, Bondarenko I, et al. P268 phase I/IIb clinical trial
comparing PK and safety of trastuzumab and its biosimilar candidate CT-P6.
Breast 2013; 22:S108.
76. Stenina MB, Ignatova E, Frolova MA, et al. Pharmacokinetics and safety of BCD-
022, trastuzumab biosimilar candidate, compared to Herceptin in patients. J Clin
Oncol 2014; 32 (abstract e11576).
77. ClinicalTrials.gov [Web site]. Efﬁcacy and safety study of ABP 980 compared
with trastuzumab in subjects with HER2 positive early breast cancer (Lilac),
Available at: https://www.clinicaltrials.gov/ct2/show/NCT01901146?term¼
NCT01901146&rank¼1 2013. Accessed: April 7, 2017.
78. von Minckwitz G, Ponomarova O, Morales S, Zhang N, Hanes V. Efﬁcacy and
safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early
breast cancer. Ann Oncol 2017; 28 (abstract 151PD).
79. Generics and Biosimilars Initiative. Amgen submits trastuzumab biosimilar to
EMA, Available at: http://gabionline.net/Biosimilars/News/Amgen-submits-
trastuzumab-biosimilar-to-EMA?utm_source¼GONL6&utm_campaign¼88771
90ab3-GONLþV17C24-C26&utm_medium¼email&utm_term¼0_bfb08b6fa
4-8877190ab3-150179273 2017. Accessed: April 17, 2017.
80. Generics and Biosimilars Initiative. Two trastuzumab biosimilars submitted to
FDA, Available at: http://www.gabionline.net/Biosimilars/News/Two-trastuzu
mab-biosimilars-submitted-to-FDA 2017. Accessed: October 13, 2017.
81. ClinicalTrials.gov [Web site]. A safety and efﬁcacy study of BCD-022 with
paclitaxel compared to herceptin with paclitaxel in HER2-positive metastatic
breast cancer patients, Available at: https://clinicaltrials.gov/ct2/show/
NCT01764022 2013. Accessed: April 7, 2017.
82. Shustova M, Burdaeva O, Alexeev S, et al. Efﬁcacy and safety of BCD-022,
trastuzumab biosimilar candidate, compared to herceptin: results of interna-
tional multicenter randomized double blind study in patients with HER2þ mBC.
Ann Oncol 2016; 27:vi68-99.
83. ClinicalTrials.gov [Web site]. Efﬁcacy and safety evaluating study of CT-P6 in
HER2 positive early breast cancer, Available at: https://clinicaltrials.gov/ct2/show/
NCT02162667 2014. Accessed: April 7, 2017.
84. Esteva F, Baranau Y, Baryash V, et al. Double-blind, randomized phase III study
to compare the efﬁcacy and safety of trastuzumab and its biosimilar candidate
CT-P6 in HER2 positive early breast cancer (EBC). Ann Oncol 2017; 28
(abstract 152PD).
85. ClinicalTrials.gov [Web site]. Demonstrate efﬁcacy and safety of metastatic breast
cancer (compare), Available at: https://clinicaltrials.gov/ct2/show/
NCT01084876. Accessed: March 1, 2018.
86. Im Y, Odarchenko P, Grecea D, et al. Double-blind, randomized, parallel group,
phase III study to demonstrate equivalent efﬁcacy and comparable safety of CT-
P6 and trastuzumab, both in combination with paclitaxel, in patients with
metastatic breast cancer (MBC) as ﬁrst-line treatment. J Clin Oncol 2013; 31
(abstract 629).Clinical Breast Cancer April 201887. FirstWordPharma, Celltrion receives EU approval for trastuzumab biosimilar,
Available at: https://www.ﬁrstwordpharma.com/node/1542952 2018. Accessed:
March 1, 2018
88. Generics and Biosimilars Initiative. Trastuzumab biosimilar submitted for
approval in Japan, Available at: http://gabionline.net/Biosimilars/News/
Trastuzumab-biosimilar-submitted-for-approval-in-Japan?utm_source¼GONL6
&utm_campaign¼dc5e0100dc-GONLþV17D14-D16&utm_medium¼email
&utm_term¼0_bfb08b6fa4-dc5e0100dc-150179273 2017. Accessed: April 17,
2017.
89. Rugo HS, Barve A, Waller CF, et al. Effect of a proposed trastuzumab biosimilar
compared with trastuzumab on overall response rate in patients with ERBB2
(HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA
2017; 317:37-47.
90. Mylan. European Medicines Agency accepts marketing authorization applications
for Mylan and Biocon’s proposed biosimilars trastuzumab and pegﬁlgrastim,
Available at: http://newsroom.mylan.com/2017-11-30-European-Medicines-
Agency-Accepts-Marketing-Authorization-Applications-for-Mylan-and-Biocons-
Proposed-Biosimilars-Trastuzumab-and-Pegﬁlgrastim 2017. Accessed: March 1,
2018.
91. FiercePharma. Mylan and Biocon win FDA nod for herceptin copy and move
biosim forward in EU, Available at: https://www.ﬁercepharma.com/pharma/
mylan-and-biocon-awaiting-fda-decision-herceptin-biosim-move-forward-eu?mkt_
tok¼eyJpIjoiTnpGak5qSTBNR1kwTm1FeiIsInQiOiJhT3RYT2Uwem4rRjJXUXR6
QkppM0llQnJzXC9QbDRnSVc2VVBPTEJQNmtVT0ExdW5vdkRDZitDUUEx
QmVWcE1KWGZzRDlYcU51TStlRlZZWWhmTjVuczJTQzFrWlBvbFpSVWpKc3
JFcU12cmhKTkZGcVNyV1ArdWdmcUErYmlUR0QifQ%3D%3D&mrkid¼
801281&utm_medium¼nl&utm_source¼internal 2017. Accessed: March 1,
2018.
92. ClinicalTrials.gov [Web site]. A study of PF-05280014 [trastuzumab-Pﬁzer] or
herceptin [trastuzumab-EU] plus paclitaxel in HER2 positive ﬁrst line meta-
static breast cancer treatment (REFLECTIONS B327-02), Available at:
https://www.clinicaltrials.gov/ct2/show/NCT01989676?term¼NCT01989676
&rank¼1 2013. Accessed: April 7, 2017.
93. ClinicalTrials.gov [Web site]. A study of PF-05280014 or trastuzumab plus
taxotere and carboplatin in HER2 positive breast cancer in the neoadjuvant
setting (REFLECTIONS B327-04), Available at: https://www.clinicaltrials.gov/
ct2/show/NCT02187744?term¼NCT02187744&rank¼1 2014. Accessed:
April 7, 2017.
94. Lammers P, Dank M, Masetti R, et al. A randomized, double-blind study of PF-
05280014 (a potential biosimilar) vs trastuzumab, both given with docetaxel (D)
and carboplatin (C), as neoadjuvant treatment for operable human epidermal
growth factor receptor 2-positive (HER2þ) breast cancer. Ann Oncol 2017; 28
(abstract 154PD).
95. Pegram M, Tan-Chiu E, Freyman A, et al. A randomized, double-blind study of
PF-05280014 (a potential trastuzumab biosimilar) vs trastuzumab, both in
combination with paclitaxel, as ﬁrst-line treatment for HER2-positive metastatic
breast cancer. Ann Oncol 2017; 28 (abstract 238PD).
96. Generics and Biosimilars Initiative. Positive phase III results for Pﬁzer’s trastu-
zumab biosimilar, Available at: http://www.gabionline.net/Biosimilars/Research/
Positive-phase-III-results-for-Pﬁzer-s-trastuzumab-biosimilar 2017. Accessed:
October 13, 2017.
97. ClinicalTrials.gov [Web site]. A study to compare the effect of SB3 and herceptin in
women with HER2 positive breast cancer, Available at: https://www.clinicaltrials.
gov/ct2/show/NCT02149524?term¼NCT02149524&rank¼1 2014. Accessed:
April 7, 2017.
98. Pivot XB, Bondarenko I, Dvorkin M, et al. A randomized, double-blind, phase
III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in
patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
J Clin Oncol 2017; 35 (abstract 509).
99. Pivot X, Bondarenko I, Nowecki Z, et al. One-year safety, immunogenicity, and
survival results from a phase III study comparing SB3 (a proposed trastuzumab
biosimilar) and originator trastuzumab in HER2-positive early breast cancer
treated with neoadjuvant-adjuvant treatment. Ann Oncol 2017; 28 (abstract
153PD).
100. Generics and Biosimilars Initiative. FDA accepts applications for adalimumab and
trastuzumab biosimilars, Available at: http://gabionline.net/Biosimilars/News/
FDA-accepts-applications-for-adalimumab-and-trastuzumab-biosimilars?utm_
source=GONL6&utm_campaign=0085a91427-EMAIL_CAMPAIGN_2018_
02_02&utm_medium=email&utm_term=0_bfb08b6fa4-0085a91427-150179273
2018. Accessed: March 1, 2018.
101. Deloitte. Winning with biosimilars: opportunities in global markets, Available at:
https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-he
alth-care/us-lshc-biosimilars-whitepaper-ﬁnal.pdf 2015. Accessed: October 17,
2017.
102. Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of bio-
similars in central and eastern European countries. Front Pharmacol 2017; 8:288.
103. Mack A. Norway, biosimilars in different funding systems. What works? GaBi J
2015; 4:90-2.
104. Remuzat C, Kapusniak A, Caban A, et al. Supply-side and demand-side policies
for biosimilars: an overview in 10 European member states. J Mark Access Health
Policy 2017; 5:1307315.
105. Vogler S, Schneider P. Do pricing and usage-enhancing policies differ between
biosimilars and generics? Findings from an international survey. GaBi J 2017; 6:
79-88.
Kimberly Blackwell et al
106. Aitken M. Delivering on the potential of biosimilar medicines: the role of
functioning competitive markets, Available at: https://www.iqvia.com/-/media/
iqvia/pdfs/institute-reports/delivering-on-the-potential-of-biosimilar-medicines.pdf
2016. Accessed: October 17, 2017.
107. Cesarec A, Likic R. Budget impact analysis of biosimilar trastuzumab for the
treatment of breast cancer in Croatia. Appl Health Econ Health Policy 2017; 15:
277-86.
108. Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the value of
biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics
2017; 35:1047-62.
109. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag
Care 2015; 21:s331-40.
110. European Medicines Agency. Committee for Medicinal Products for Human Use
(CHMP). CHMP assessment report: Herceptin (trastuzumab), Available at:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_
Report_-_Variation/human/000278/WC500153233.pdf 2013. Accessed:
October 20, 2017.
111. Ismael G, Hegg R, Muehlbauer S, et al. Subcutaneous versus intravenous
administration of (neo)adjuvant trastuzumab in patients with HER2-positive,clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multi-
centre, randomised trial. Lancet Oncol 2012; 13:869-78.
112. Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous
formulation of trastuzumab for HER2-positive early breast cancer:
updated results from the phase III HannaH study. Ann Oncol 2015; 26:
320-5.
113. Pivot X, Gligorov J, Muller V, et al. Preference for subcutaneous or intra-
venous administration of trastuzumab in patients with HER2-positive early
breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013;
14:962-70.
114. Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B. Comparison
of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial
in healthy male volunteers and patients with HER2-positive breast cancer. J Clin
Pharmacol 2013; 53:192-201.
115. Robertson J, Barr R, Shulman LN, Forte GB, Magrini N. Essential medicines for
cancer: WHO recommendations and national priorities. Bull World Health Organ
2016; 94:735-42.
116. The Lancet. Improving access to biosimilars in low-income countries. Lancet
2017; 389:1860.Clinical Breast Cancer April 2018 - 113
